Prospects for a Grail IPO remain unclear. The biotech filed to go public last fall, but it struck a deal to be acquired by Illumina (ILMN) for $8 billion instead. As of mid-2021, regulators were still reviewing the deal for approval.
While the merger is still unclear, shares of Illumina are currently available for purchase.
December 16: Illumina has criticized EU regulators in court for the Commission’s scrutiny of its acquisition of Grail.
August 18: US biotech company Illumina acquires Grail, even though the European Commission has not completed its review of the acquisition.
April 20: In response to competition concerns, EU antitrust regulators will examine Illumina’s proposed acquisition of Grail.
March 30: The Federal Trade Commission has filed to block Illumina’s proposed acquisition of Grail.
If Grail goes public independently, you’ll be able to buy shares after the IPO happens. You can also buy shares of Illumina now — though it’s unclear whether Illumina’s acquisition of Grail will hold.
Grail filed a registration form with the US Securities and Exchange Commission (SEC) to go public on the Nasdaq Global Select Market under the ticker symbol GRAL. Not yet an official IPO, this is one of the first steps of taking a private company public.
The exact IPO date has not been announced. There's no news yet about how much the stock will cost when it goes public. We'll update this page with more information as it becomes available.
It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Looking at the performance of similar companies can help you decide if now is a good time to buy Grail stock.
See how the following stocks are performing, and view details like market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Modak has no monthly fee, but it’s slim on features. Greenlight starts at $5.99 but is a value for big families.
Get the capital your business needs to grow with repayments that adapt to your revenue.
We’ve compared the best cash advance apps for quick cash — find the right one for your needs.
A review of Beyond Finance, a company that offers debt settlement and consolidation loans.
1. Make a budget 2. Create a savings plan 3. Automate savings 4. Pay yourself first 5. Use a high-yield account 6. Do a savings challenge…
To save $10K: 1. Automate savings 2. Invest 3. Budget 4. Open a high-yield savings account 5. Cut down on spending 6. Pay off debt…
A review of Arrowhead Advance, a tribal lender that charges interest rates up to 830% and has numerous bad reviews.
There aren’t many personal loans with no credit check. True no credit check loans include cash advance apps, payday loans and more.
Compare business cash advances from a variety of lenders and the pros and cons of each option.
Top picks for loans like Lendumo, with more competitive rates and a range of options for borrowers of all kinds.